Emerging applications for high-resolution MS in discovery bioanalysis

Bioanalysis

Volumn 3, Issue 22, 2011, Pages 2485-2489

  Emary, W Bart ^a   Zhang, Nanyan Rena ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biomarkers; Drug discovery; High resolution MS; Metabolite identification; Pharmacokinetics; Qualitative quantitative workflow; Quantitation; SiRNA; Toxicity

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; DRUG METABOLITE; SMALL INTERFERING RNA;

ACCURACY; ALZHEIMER DISEASE; BIOASSAY; CLINICAL EFFECTIVENESS; DATA ANALYSIS SOFTWARE; DISEASE MARKER; DRUG METABOLISM; FILTRATION; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROCESS MONITORING; PROTEIN ANALYSIS; REACTION ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; TISSUE CHARACTERIZATION;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MASS SPECTROMETRY; RNA, SMALL INTERFERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 82455188364     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.245     Document Type: Review

References (22)

1. Bateman KP, Kellmann M, Muenster H, Papp R, Taylor L. Quantitative-qualitative data acquisition using a Benchtop Orbitrap Mass Spectrometer. J. Am. Soc. Mass Spectrom. 20(8), 1441-1450 (2009).
2. Zhang ZP, Zhu MS, Tang W. Metabolite identification and profiling in drug design: current practice and future directions. Curr. Pharm. Des. 15(19), 2220-2235 (2009).
3. Zhang NR, Yu S, Tiller P, Yeh S, Mahan E, Emary WB. Quantitation of small molecules using high-resolution accurate mass spectrometers - a different approach for analysis of biological samples. Rapid Comm. Mass Spectrom. 23(7), 1085-1094 (2009).
4. Ramanathan R, Jemal M, Ramagiri S et al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 46(6), 595-601 (2011).
5. Paweletz CP, Wiener MC, Bondarenko AY et al. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high-resolution differential mass spectrometry. J. Proteome Res. 9(3), 1392-1401 (2010).
6. Zhang HY, Petrone L, Kozlosky J, Tomlinson L, Cosma G, Horvath J. Pooled sample strategy in conjunction with high-resolution liquid chromatography-mass spectrometry-based background subtraction to identify toxicological markers in dogs treated with ibipinabant. Anal. Chem. 82(9), 3834-3839 (2010).
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001).
8. Daniels L. Combining multiple biomarkers for cardiovascular risk assessment: more is usually better - up to a point. Bioanalysis 3(15), 1679-1682 (2011).
9. Rompp A, Guenther S, Schober Y et al. Histology by mass spectrometry: label-free tissue characterization obtained from high-accuracy bioanalytical imaging. Angew. Chem. Int. Ed. 49(22), 3834-3838 (2010).
10. Wisniewski JR, Ostasiewicz P, Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J. Proteome Res. 10, 3040-3049 (2011).
11. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10(5), 345-352 (2010).
12. McAlister GC, Phanstiel D, Wenger CD, Lee MV, Coon JJ. Analysis of tandem mass spectra by FTMS for improved large-scale proteomics with superior protein quantification. Anal. Chem. 82(1), 316-322 (2010).
13. Shi B, Keough E, Matter, A, Leander K et al. Biodistribution of small interfering RNA at the organ and cellular levels after Li nanoparticle-mediated delivery. J. Histochem. Cytochem. 59(8), 727-740 (2011).
14. Li G, Crowe D, Beverly M. LC-MS analysis of therapeutic siRNA in mouse liver. Presented at: The 59th ASMS Conference on Mass Spectrometry and Allied Topics. Denver, CO, USA, 5-9 June 2011.
15. Zou Y, Tiller P, Chen IW, Beverly M, Hochman J. Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 22(12), 1871-1881 (2008).
16. Takami T, Nishida Y, Shioyama S, Goto R. Quantitative and qualitative analysis of an siRNA and its degradation products in plasma by LC-MS/MS. Presented at: The 59th ASMS Conference on Mass Spectrometry and Allied Topics. Denver, CO, USA, 5-9 June 2011.
17. Mortishire-Smith RJ, O'Connor D, Castro-Perez JM, Kirby J. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun. Mass Spectrom. 19(18), 2659-2670 (2005).
18. Zhu MS, Ma L, Zhang DL et al. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high-resolution mass spectrometry data. Drug Metab. Dispos. 34(10), 1722-1733 (2006).
19. Zhang HY, Zhang DL, Ray K, Zhu MS. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J. Mass Spectrom. 44(7), 999-1016 (2009).
20. Chen WQ, Caceres-Cortes J, Zhang HY, Zhang DL, Humphreys WG, Gan JP. Bioactivation of substituted thiophenes including a-chlorothiophene-containing compounds in human liver microsomes. Chem. Res. Toxicol. 24(5), 663-669 (2011).
21. Holman SW, Wright P, Langley GJ. High-throughput approaches towards the definitive identification of pharmaceutical drug metabolites. 2. An example of how unexpected dissociation behavior could preclude correct assignment of sites of metabolism. Rapid Commun. Mass Spectrom. 23(13), 2017-2025 (2009).
22. Cooks RG. Creativity through instrumentation. Anal. Chem. 57(7), A823-A843 (1985).